sign in sign up
<<
Home , Cloforex, List of withdrawn drugs

List of withdrawn drugs

WRITEN BY LAIMA JONUSIENE

To prove that the drug companies make mistakes with our lives we publish this list. Drugs are rushed onto the market for profit. The testing of the drugs is on the major indication. Side effects are NOT tested pre and post. Side effects are observed NOT tested. The expense of pre and post side effect testing is astounding. So it is not done. Side effects are then seen in the public use and a drug is removed from the market after killing or hurting people.

There is a special law that prohibits you from suing a drug company for damages unless you can prove they knew it was harmful and sold it anyway. This means there is even less need to test side effects and or report them during the testing process. https://www.youtube.com/watch?v=h7Sd0uBc6eE - How a drug pill is brought to the market.

Some drugs have been withdrawn from the market because of risks to the patients. Usually this has been prompted by unexpected adverse effects that were not detected during Phase III clinical trials and were only apparent from postmarketing surveillance data from the wider patient community. This list is not limited to drugs that were ever approved by the FDA. Some of them (, , , and , for example) were approved to be marketed in Europe but had not yet been approved for marketing in the U.S., when side effects became clear and their developers pulled them from the market. Likewise LSD was never approved for marketing in the U.S. https://www.youtube.com/watch?v=7K3KR9of4gw

As we see from this list there is a serious flaw in our appraisal process. Withdrawals from market

Withdrawn Drug name Remarks

Withdrawn because of risk of teratogenicity; returned 1950s–

Thalidomide to market for use in and multiple myeloma 1960s under FDA orphan drug rules Lysergic acid diethylamide 1950s– Marketed as a psychiatric cure-all; withdrawn after it (LSD) 1960s became widely used recreationally Withdrawn because of risk of teratogenicity = birth

Diethylstilbestrol 1970s defects and 1978 Withdrawn because of risk of lactic acidosis

Ticrynafen 1982 Withdrawn because of risk of hepatitis Withdrawn worldwide because of risk of Guillain-

Zimelidine 1983 Barré syndrome An ingredient in "A.P.C." tablet; withdrawn because

Phenacetin 1983 of risk of cancer and kidney disease

Methaqualone 1984 Withdrawn because of risk of addiction and overdose (Merital) 1986 Withdrawn because of risk of hemolytic anemia Withdrawn in the United Kingdom because of risk of

Triazolam 1991 psychiatric adverse drug reactions. This drug continues to be available in the U.S. Withdrawn in the United States because of allergic

Temafloxacin 1992 reactions and cases of hemolytic anemia, leading to three patient deaths.[1] Withdrawn in the United States because of an Flosequinan (Manoplax) 1993 increased risk of hospitalization or death (Ananxyl) 1996 Withdrawn because of rare but serious . Withdrawn because of rare but serious cases of toxic (Trancopal) 1996 epidermal necrolysis Fen-phen (popular remains on the market, combination of 1997 and fenfluramine – later withdrawn as caused heart and phentermine) valve disorder Tolrestat (Alredase) 1997 Withdrawn because of risk of severe hepatotoxicity (Seldane, Withdrawn because of risk of cardiac ; 1998 Triludan) superseded by fexofenadine Withdrawn because of dangerous interactions with (Posicor) 1998 other drugs

Etretinate 1990s Risk of birth defects; narrow therapeutic index (Micturin) 1991 Prolonged QT interval (Tasmar) 1998 Hepatotoxicity Withdrawn in Sweden and Norway because of (Restoril, diversion, abuse, and a relatively high rate of Euhypnos, Normison, 1999 overdose deaths in comparison to other drugs of its Remestan, Tenox, Norkotral) group. This drug continues to be available in most of the world including the U.S., but under strict controls. (Hismanal) 1999 Arrhythmias because of interactions with other drugs (Raxar) 1999 Prolonged QT interval Withdrawn because of risk of hepatotoxicity; (Rezulin) 2000 superseded by and Withdrawn because of risk of fatal complications of (Lotronex) 2000 constipation; reintroduced 2002 on a restricted basis Withdrawn in many countries because of risk of (Propulsid) 2000s cardiac arrhythmias Withdrawn because of hepatotoxicity, dermatological (Survector) 2000 side effects, and abuse potential. Withdrawn because of risk of stroke in women under 2000 50 years of age when taken at high doses (75mg twice (Propagest, Dexatrim) daily) for weight loss. (Trovan) 2001 Withdrawn because of risk of liver failure (Baycol, 2001 Withdrawn because of risk of Lipobay) Withdrawn in many countries because of risk of fatal Rapacuronium (Raplon) 2001 bronchospasm (Vioxx) 2004 Withdrawn because of risk of Co-proxamol (Distalgesic) 2004 Withdrawn in the UK due to overdose dangers. Withdrawn in Canada because of risk of stroke. See Health Canada press release. The ban was later lifted mixed salts 2005 because the death rate among those taking

(Adderall XR) XR was determined to be no greater than those not taking Adderall. extended- Withdrawn because of a high risk of accidental 2005 release (Palladone) overdose when administered with Withdrawn from U.K. market because of (Melleril) 2005 cardiotoxicity Withdrawn from U.S. market because of (Cylert) 2005 hepatotoxicity Voluntarily withdrawn from U.S. market because of (Tysabri) 2005-2006 risk of Progressive multifocal leukoencephalopathy (PML). Returned to market July, 2006. Withdrawn because of risk of hepatotoxicity (liver Ximelagatran (Exanta) 2006 damage). (Permax) 2007 Voluntarily withdrawn in the U.S. because of the risk of heart valve damage. Still available elsewhere. Withdrawn because of imbalance of cardiovascular ischemic events, including heart attack and stroke. (Zelnorm) 2007 Was available through a restricted access program until April 2008. Withdrawn because of increased risk of (Trasylol) 2007 complications or death; permanently withdrawn in 2008 except for research use Withdrawn in the UK due to poor sales caused by Inhaled (Exubera) 2007 national restrictions on prescribing, doubts over long term safety and too high a cost Progressively withdrawn around the world because of Lumiracoxib (Prexige) 2007-2008 serious side effects, mainly liver damage Withdrawn around the world because of risk of Rimonabant (Accomplia) 2008 severe depression and suicide Withdrawn because of increased risk of progressive (Raptiva) 2009 multifocal leukoencephalopathy; to be completely withdrawn from market by June 2009 Withdrawn in Europe because of increased (Reductil) 2010 cardiovascular risk. This drug continues to be available in the U.S. Withdrawn in the U.S. due to increased risks of veno- occlusive disease and based on results of a in which it showed no benefit in acute myeloid Gemtuzumab ozogamicin 2010 leukemia (AML) (Mylotarg)

This list is from 1999. The following drug products were withdrawn or removed from the market because such drug products or components of such drug products were found to be unsafe or not effective. The following drug products may not be compounded under the exemptions provided by section 503A(a) of the Federal Food, Drug, and Cosmetic Act: phosphate: All drug products containing adenosine phosphate. Adrenal cortex: All drug products containing adrenal cortex. Azaribine: All drug products containing azaribine. : All drug products containing benoxaprofen. Bithionol: All drug products containing bithionol. sodium: All drug products containing bromfenac sodium. Butamben: All parenteral drug products containing butamben. Camphorated oil: All drug products containing camphorated oil. Carbetapentane citrate: All oral gel drug products containing carbetapentane citrate. Casein, iodinated: All drug products containing iodinated casein. Chlorhexidine gluconate: All tinctures of chlorhexidine gluconate formulated for use as a patient preoperative skin preparation. : All drug products containing chlormadinone acetate. : All drug products containing chloroform. Cobalt: All drug products containing cobalt salts (except radioactive forms of cobalt and its salts and cobalamin and its derivatives). Dexfenfluramine hydrochloride: All drug products containing dexfenfluramine hydrochloride. Diamthazole dihydrochloride: All drug products containing diamthazole dihydrochloride. Dibromsalan: All drug products containing dibromsalan. : All oral and parenteral drug products containing 25 milligrams or more of diethylstilbestrol per unit dose. Dihydrostreptomycin sulfate: All drug products containing dihydrostreptomycin sulfate. Dipyrone: All drug products containing dipyrone. hydrochloride: All drug products containing encainide hydrochloride. Fenfluramine hydrochloride: All drug products containing fenfluramine hydrochloride. Flosequinan: All drug products containing flosequinan. Gelatin: All intravenous drug products containing gelatin. Glycerol, iodinated: All drug products containing iodinated glycerol. Gonadotropin, chorionic: All drug products containing chorionic gonadotropins of animal origin. Mepazine: All drug products containing mepazine hydrochloride or mepazine acetate. Metabromsalan: All drug products containing metabromsalan. hydrochloride: All parenteral drug products containing methamphetamine hydrochloride. : All drug products containing methapyrilene. Methopholine: All drug products containing methopholine. Mibefradil dihydrochloride: All drug products containing mibefradil dihydrochloride. sulfate: All parenteral drug products containing neomycin sulfate. Nitrofurazone: All drug products containing nitrofurazone (except topical drug products formulated for dermatalogic application). Nomifensine maleate: All drug products containing nomifensine maleate. Oxyphenisatin: All drug products containing oxyphenisatin. Oxyphenisatin acetate: All drug products containing oxyphenisatin acetate. : All drug products containing phenacetin. Phenformin hydrochloride: All drug products containing phenformin hydrochloride. Pipamazine: All drug products containing pipamazine. Potassium arsenite: All drug products containing potassium arsenite. Potassium chloride: All solid oral dosage form drug products containing potassium chloride that supply 100 milligrams or more of potassium per dosage unit (except for controlled-release dosage forms and those products formulated for preparation of solution prior to ingestion). Povidone: All intravenous drug products containing povidone. : All oral dosage form drug products containing more than 1 milligram of reserpine. Sparteine sulfate: All drug products containing sparteine sulfate. : All drug products containing sulfadimethoxine. : All drug products containing sulfathiazole (except those formulated for vaginal use). : All drug products containing suprofen (except ophthalmic solutions). Sweet spirits of nitre: All drug products containing sweet spirits of nitre. hydrochloride: All drug products containing temafloxacin hydrochloride. Terfenadine: All drug products containing terfenadine. 3,3',4',5-tetrachlorosalicylanilide: All drug products containing 3,3',4',5-tetrachlorosalicylanilide. : All liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 milligrams/milliliter. Ticrynafen: All drug products containing ticrynafen. Tribromsalan: All drug products containing tribromsalan. Trichloroethane: All aerosol drug products intended for inhalation containing trichloroethane. Urethane: All drug products containing urethane. Vinyl chloride: All aerosol drug products containing vinyl chloride. Zirconium: All aerosol drug products containing zirconium. sodium: All drug products containing zomepirac sodium.

Dated: October 1, 1998.

Significant withdrawals world wide

Withdr Drug name Country Remarks awn

Adderall XR 2005 Canada Risk of stroke[1] The ban was later lifted because the Withdr Drug name Country Remarks awn

death rate among those taking Adderall XR was determined to be no greater than those not taking Adderall.

Liver toxicity; serious liver

Alatrofloxacin 2006 Worldwide injury leading to liver transplant; death.[2]

[3] 1979 UK Vasculitis, Rash.

Not approved in the US, withdrawn in France in 1994[4] and the rest of the Alpidem (Ananxyl) 1995 Worldwide market in 1995 because of rare but serious hepatotoxicity.[3][5]

Serious gastrointestinal adverse events; ischemic colitis; severe Alosetron (Lotronex) 2000 US constipation.[2] Reintroduced 2002 on a restricted basis[citation needed]

Althesin (=Alphaxolone amine 1984 France, Germany, UK .[3] ptine +Alphadolone) Withdr Drug name Country Remarks awn

Hepatotoxicity, dermatologi cal side effects, Amineptine (Survector) 1999 France, US and abuse potential.[6] Reas on:

risk of agranulocytosis;

Aminopyrine 1999 France, Thailand severe .[3]

[3] 1980 Norway Self poisoning.

Dermatologic and

Amoproxan 1970 France ophthalmic toxicity.[3]

[3] Anagestone acetate 1969 Germany Animal carcinogenicity.

Unspecific experimental

Antrafenine 1984 France toxicity.[3]

Aprotinin (Trasylol) 2008 US Increased risk of death.[2]

Not for reasons of safety or Ardeparin (Normiflo) 2001 US efficacy.[7]

US, Malaysia, Multiple Astemizole (Hismanal) 1999 Fatal [2][3] Nonspecified Markets Withdr Drug name Country Remarks awn

[3] Azaribine 1976 US Thromboembolism.

[3] 1993) Spain Hepatotoxicity.

Liver and kidney failure;

Benoxaprofen 1982 Germany,Spain, UK, US gastrointestinal bleeding; ulcers.[2][3]

[3] Benzarone 1992 Germany Hepatitis.

[3] Benziodarone 1964 France, UK Jaundice.

Renal toxicity, animal

Beta-ethoxy-lacetanilanide 1986 Germany carcinogenicity.[3]

[8] 2004 Netherlands Fatal overdose.

[3] Bithionol 1967 US Dermatologic toxicity.

[3] Broazolam 1989 UK Animal carcinogenicity.

Severe hepatitis and liver

Bromfenac 1998 US failure (some requiring transplantation).[2] Withdr Drug name Country Remarks awn

[3] 1986 Germany Renal toxicity.

[3] Buformin 1978 Germany Metabolic toxicity.

[9] Bunamiodyl 1963) Canada, UK, US Nephropathy.

Butamben (Efocaine)(Butofor Dermatologic toxicity; 1964 US me) psychiatric Reactions.[3]

[3] 1986 Germany Animal Carcinogenicity.

Cerivastatin (Baycol, Lipobay) 2001 US Risk of rhabdomyolysis[2]

Chlormadinone (Chlormenadi 1970 UK, US Animal Carcinogenicity.[3] one)

Hepatotoxicity; Steven- European Union, US, Chlormezanone (Trancopal) 1996 Johnson Syndrome; Toxic South Africa, Japan Epidermal Necrolysis.[3]

[3] 1969 Germany Cardiovascular Toxicity.

France, Germany, [3] Cianidanol 1985 Hemolytic Anemia. Spain, Sweden Withdr Drug name Country Remarks awn

[3] 1987 Spain Agranulocytosis.

Risk of fatal cardiac Cisapride (Propulsid) 2000 US arrhythmias[2]

France, Germany, UK, [3] Clioquinol 1973 Neurotoxicity. US

Ventricular arrhythmia, QT-

Clobutinol 2007 Germany prolongation.[10]

[3] 1969 Germany Cardiovascular toxicity.

[3] Clomacron 1982 UK Hepatotoxicity.

[3] Clometacin 1987 France Hepatotoxicity.

Co-proxamol (Distalgesic) 2004 UK Overdose dangers.

[3] 1980 Norway Self poisoning.

[3] 1987 France Hepatotoxicity.

[11] Dantron 1963 Canada, UK, US Genotoxicity. Withdr Drug name Country Remarks awn

[3] Dexfenfluramine 1997 European Union, UK, US Cardiac valvular disease.

Propoxyphene (Darvocet/Darv Increased risk of heart 2010 Worldwide on) attacks and stroke.[12]

[3] Diacetoxydiphenolisatin 1971 Australia Hepatotoxicity.

Risk of teratogenicity[citation

Diethylstilbestrol 1970s needed]

[3] Difemerine 1986 Germany Multi-Organ toxicities.

[3] Dihydrostreptomycin 1970 US Neuropsychiatric reaction.

[3] Dilevalol 1990 UK Hepatotoxicity.

Dimazol (Diamthazole) 1972 France, US Neuropsychiatric reaction.[3]

Voluntarily withdrawn from market by Lily.[13]:12 Reintroduced as a in Dimethylamylamine (DMAA) 1983 US 2006;[13]:13 and in 2013 the FDA started work to ban it due to cardiovascular problems[14] Withdr Drug name Country Remarks awn

Uterine hypotonus, fetal

Dinoprostone 1990 UK distress.[3]

Agranulocytosis, Dipyrone() 1975 UK, US, Others anaphylactic reactions.[3]

Cardiovascular and

Dithiazanine iodide 1964 France, US metabolic reaction.[3]

Drug intereactions,

Dofetilide 2004 Germany prolonged QT.[10]

Lack of efficacy as shown Drotrecogin alfa (Xigris) 2011 Worldwide by PROWESS-SHOCK study[citation needed]

[3] 1998 Spain Hepatotoxicity.

Withdrawn because of increased risk of Efalizumab (Raptiva) 2009 Germany progressive multifocal leukoencephalopathy[10]

[2][3] Encainide 1991 UK, US Ventricular arrhythmias.

[15] Ethyl carbamate 1963 Canada, UK, US, Carcinogenicity. Withdr Drug name Country Remarks awn

Withdrawn US (1999). Risk

Etretinate 1989 France for birth defects.[2][3]

[3] Exifone 1989 France Hepatotoxicity.

Fen-phen (popular combination 1997 Cardiotoxicity offenfluramine and phentermin e)

Cutaneous reactions;

Fenclofenac 1984 UK animal carcinogenicity.[3]

Jaundice, elevated hepatic

Fenclozic acid 1970 UK, US enzymes.[3]

European Union, UK, Cardiac valvular disease,

Fenfluramine 1997 US, India, South Africa, pulmonary hypertension, others cardiac fibrosis.[3][16]

[3] 1990 New Zealand Asthma mortality.

Cutaneous reaction,

Feprazone 1984 Germany, UK multiorgan toxicity.[3]

[3] Fipexide 1991 France Hepatotoxicity. Withdr Drug name Country Remarks awn

Increased mortality at Flosequinan (Manoplax) 1993 UK, US higher doses; increased hospitalizations.[2][3]

[3] 1991 France Abuse.

Increased risk of

Gatifloxacin 2006 US dysglycemia.[2]

Gemtuzumab No improvement in clinical 2010 US ozogamicin (Mylotarg) benefit; risk for death.[2]

[3] 1984 France, Germany Anaphylaxis.

Withdrawn Germany, Cardiac repolarization; QT Grepafloxacin (Raxar) 1999 UK, US others interval prolongation.[2]

High risk of accidental overdose when Hydromorphone (Palladone)] 2005 administered with alcohol. Still sold in most of the world including the US

[3] Ibufenac 1968 UK Hepatotoxicity, jaundice.

[3] 1985 France Agranulocytosis. Withdr Drug name Country Remarks awn

Animal carcinogenicity,

Indoprofen 1983 Germany, Spain, UK gastrointestinal toxicity.[3]

[3] Iodinated casein strophantin 1964 US Metabolic reaction.

Interactions with food

Iproniazid 1964 Canada products containing .[17]

[3] Isaxonine phosphate 1984 France Hepatotoxicity.

France, Germany, Stevens johnson

Isoxicam 1983 Spain, others syndrome.[3]

[10] Kava 2002 Germany Hepatotoxicity.

Hemorrhage, renal

Ketorolac 1993 France, Germany, others Failure.[3]

Eosinophilic myalgia

[3] L- 1989 Germany, UK syndrome. Still sold in the US

Still used as veterinary drug (Ergamisol) 1999 US and as a human antihelminthic in many markets; listed on the WHO Withdr Drug name Country Remarks awn

List of Essential Medicines. In humans, it was used to treat melanoma before it was withdrawn foragranulocytosis[citation needed].

Cardiac arrhythmias and

Levomethadyl acetate 2003 US cardiac arrest.[2]

2007– Lumiracoxib (Prexige) Worldwide Liver damage 2008

Marketed as a psychiatric drug; withdrawn after it Lysergic acid 1950s– became widely used diethylamide (LSD) 1960s recreationally. Now illegal in most of the world.

Hepatotoxicity, drug

Mebanazine 1975 UK intereaction.[3]

France, Germany, UK, [3] Methandrosteronolone 1982 Off-label abuse. US, others

[3] Methapyrilene 1979 Germany, UK, US Animal carcinogenicity.

South Africa (1971), Withdrawn because of risk 1984 India (1984), United of addiction and overdose[18][ Withdr Drug name Country Remarks awn

Nations (1971-1988) 19]

[3] 1990 UK, others Uveitis.

Unspecific experimental

Metofoline 1965 US toxicity.[3]

European Union, Fatal arrhythmia, drug

Mibefradil 1998 Malaysia, US, others interactions.[2][3]

[3] 1996 France Convulsions.

[3] 1993 France Necrotic hepatitis.

France,

[3] Muzolimine 1987 Germany,European Polyneuropathy. Union

Voluntarily withdrawn from US market because of risk 2005– of Progressive multifocal Natalizumab (Tysabri) US 2006 leukoencephalopathy (PML) . Returned to market July, 2006.

Branded version withdrawn

Nefazodone 2007 US, Canada, others by originator in several countries in 2007 for Withdr Drug name Country Remarks awn

hepatotoxicity. Generic versions available.[20]

Hepatotoxicity, drug

Nialamide 1974 UK, US intereaction.[3]

[3] Nikethamide 1988) multiple markets CNS Stimulation.

Hepatic and hematologic

Nitrefazole 1984) Germany toxicity.[3]

Hemolytic Anemia, 1981- France, Germany,

Nomifensine hepatotoxicity, serious 1986 Spain, UK, US, others hypersensitive reactions.[2][3]

[21] Oxeladin 1976 Canada, UK, US (1976) Carcinogenicity.

Bone marrow suppression, 1984- UK, US, Germany,

Oxyphenbutazone Steven Johnson 1985 France, Canada Syndrome.[3][22]

Australia, France, Oxyphenisatin (Phenisatin) Hepatotoxicity.[3] Germany, UK, US

No improvement in clinical

Ozogamicin 2010 US benefit; risk for death; veno- occlusive disease.[2] Withdr Drug name Country Remarks awn

Withdrawn from US in 2005. Pemoline (Cylert) 1997 Canada, UK Hepatotoxicity[23] Reason:he patotoxicity.[3]

[3] 1980 Norway Self poisoning.

Withdrawn for inability to produce

Pentylenetetrazol 1982 effective convulsive therapy, and for causing seizures.

Risk for heart valve Pergolide (Permax) 2007 US damage.[2]

Neurologic and hepatic

Perhexilene 1985 UK, Spain toxicity.[3]

An ingredient in "A.P.C." tablet; withdrawn because of risk of cancer and kidney

Phenacetin 1975 Canada disease[24] Germany Denmark, UK, US, others Reason: nephropathy.[3]

Phenformin and Buformin 1977 France, Germany US Severe lactic acidosis[3] Withdr Drug name Country Remarks awn

[25] Phenolphthalein 1997 US Carcinogenicity.

Hepatotoxicity, drug

Phenoxypropazine 1966 UK intereaction.[3]

Off-label abuse,

Phenylbutazone 1985 Germany hematologic toxicity.[3]

Phenylpropanolamine(Propag 2000 Canada, US Hemorrhagic stroke.[26][27] est,Dexatrim)

Pifoxime (=Pixifenide) 1976 France Neuropsychiatric reaction.[3]

[3][28]:223 1990 France, Germany, Spain Liver toxicity.

Canada,France, Cardiac arrythmia[29] and

Prenylamine 1988 Germany, UK, US, death.[3] others

[3] 1989 Germany Respiratory reaction.

[3] 1965 UK Animal carcinogenicity.

[3] 1983 UK Allergy. Withdr Drug name Country Remarks awn

Spain, France, Italy, Immunoallergic,

Proxibarbal 1998 Portugal, Turkey thrombocytopenia.[3]

[3] 1979 France Abuse.

Withdrawn in many Rapacuronium (Raplon) 2001 US, multiple markets countries because of risk of fatal bronchospasm[2]

[3] 1993 UK, others Aplastic anemia.

Risk of severe depression Rimonabant (Acomplia) 2008 Worldwide and suicide[10]

Risk of myocardial Rofecoxib (Vioxx) 2004 US infarction and stroke[2]

Risk of heart attacks and Rosiglitazone (Avandia) 2010 Europe death. This drug continues to be available in the US

[3] France, Norway, others. Self poisoning.

Arrhythmia and sudden

Sertindole 1998 European Union cardiac death[3][30] Withdr Drug name Country Remarks awn

Australia,[31] Canada,[32] C hina,[33] the European Union (EU),[34] Hong Kong,[35] India,[36]Mexico, Increased risk of heart Sibutramine (Reductil/Meridia) 2010 New Zealand,[37] the attack and stroke.[2] Philippines,[38] Thailand,[39 ] the United Kingdom,[40] and the United States[41]

[10] 2010 Germany Hepatotoxicity.

Drug interaction and

Sorivudine 1993 Japan deaths.[citation needed]

QT prolongation and

Sparfloxacin 2001 US phototoxicity.[2]

Dermatologic, hematologic

Sulfacarbamide 1988 Germany and hepatic reactions .[3]

[3] Sulfamethoxydiazine 1988 Germany Unknown.

Dermatologic and

Sulfamethoxypyridazine 1986 UK hematologic reactions.[3]

[3] Suloctidyl 1985 Germany, France, Spain Hepatotoxicity. Withdr Drug name Country Remarks awn

1986- Flank pain, decreased

Suprofen UK, Spain, US 1987 kidney function.[2][3]

Risk for heart attack, stroke, and unstable angina.[2] Was Tegaserod (Zelnorm) 2007 US available through a restricted access program until April 2008.

Low blood sugar; hemolytic Germany, UK, US, anemia; kidney, liver

Temafloxacin 1992 others dysfunction; allergic reactions[2][3]

Allergic reactions and cases of hemolytic anemia,

Temafloxacin 1992 US leading to three patient deaths.[2]

Diversion, abuse, and a relatively high rate of overdose deaths in Temazepam (Restoril, comparison to other drugs Euhypnos, Normison, 1999 Sweden, Norway of its group. This drug Remestan, Tenox, Norkotral) continues to be available in most of the world including the US, but under strict controls. Withdr Drug name Country Remarks awn

Terfenadine (Seldane, 1997- France, South Africa, Prolonged QT interval; Triludan) 1998 Oman, others, US ventricular tachycardia[2][3]

Prolonged QT interval, Germany, UK, Spain, Terodiline (Micturin) 1991 ventricular tachycardia and others arrhythmia.[3]

Serious cutaneous

Tetrazepam 2013 European Union reactions.[42]

Withdrawn because of risk of teratogenicity;[43] returned to market for use

Thalidomide 1961 Germany in leprosy and multiple myelomaunder FDA orphan drug rules

[3][44] 1960 Canada, UK, US Neutropenia

[3] Thiobutabarbitone 1993 Germany Renal insufficiency.

Withdrawn worldwide due to Thioridazine (Melleril) 2005 Germany, UK severe cardiac arrhythmias[45][46]

Germany, France, UK, Ticrynafen(Tienilic acid) 1980 Liver toxicity and death.[3] US others Withdr Drug name Country Remarks awn

European Union, Tolcapone (Tasmar) 1998 Hepatotoxicity[3] Canada, Australia

Argentina, Canada, Italy, Tolrestat (Alredase) 1996 Severe hepatotoxicity[3] others

[3] Triacetyldiphenolisatin 1971 Australia Hepatotoxicity.

France, Netherlands, Psychiatric adverse drug

Triazolam 1991 Finland, Argentina, UK reactions, amnesia.[3][47] others

Cataracts, alopecia,

Triparanol 1962 France, US ichthyosis.[3]

[2] Troglitazone (Rezulin) 2000 US, Germany Hepatotoxicity

1999- Withdrawn because of risk Trovafloxacin (Trovan) European Union, US 2001 of liver failure[2][3]

Risk of heart attack and (Bextra) 2004 US stroke.[2]

[3] Vincamine 1987 Germany Hematologic toxicity.

[3] Xenazoic acid 1965 France Hepatotoxicity. Withdr Drug name Country Remarks awn

Ximelagatran (Exanta) 2006 Germany Hepatotoxicity[10]

Risk of Guillain-Barré syndrome, hypersensitivity

Zimelidine 1983 Worldwide reaction, hepatotoxicity[3][48][49] banned worldwide.[50]

Anaphylactic reactions and

Zomepirac 1983 UK, Germany, Spain, US non-fatal allergic reactions, renal failure[2][3]

THE SPECIAL LAW FOR THE PHARMECEUTCAL COMPANIES

In the real world of commerce, if a company sells you something that hurts somebody you can sue them for damages. The Toyota cars killed people, and they had to pay damages. But the drug companies have a special exemption to this liability. To sue them for damages you must prove they knew it would hurt before they sold it and sold it anyway. Just being hurt is not enough to get damages. You must prove that they knowingly sold a drug that could hurt.

This allows them to hurt people and make massive profits and not be held responsible for damages. But still they are sued for damages in the multi billions of dollars each year when lawyers feel they have a case and can possibly prove the company knowingly sold a harmful substance.

If we change this law and hold them responsible for all damages then the world changes.